Alemtuzumab in treatment of chronic lymphocytic leukemia
https://doi.org/10.17650/1818-8346-2009-0-3-15-22
Abstract
Efficiency of alemtuzumab (Campath) in 8 patients with chronic lymphocytic leukemia (CLL) was reported. Patients treated with alemtuzumab or alemtuzumab in combination with fludarabine (FluCam). Therapy response, overall survival and incidence of side effects were estimated. Among 5 patients with primary CLL, therapy response was 100%. Alemtuzumab was high effective in patients with relapsed and refractory CLL too. The main complications were myelosupression and infections. High efficacy of alemtuzumab in CLL therapy was shown.
About the Authors
S. S. Bessmeltsev
Russian Research Institute of Hematology and Transfusiology
Russian Federation
Russian Federation
St.-Petersburg
E. V. Litvinskaya
Russian Research Institute of Hematology and Transfusiology
Russian Federation
Russian Federation
St.-Petersburg
K. M. Abdulkadirov
Russian Research Institute of Hematology and Transfusiology
Russian Federation
Russian Federation
St.-Petersburg
E. V. Karyagina
Municipal hospital № 15
Russian Federation
Russian Federation
St.-Petersburg
References
1. Волкова М.А. Полвека в терапии хронического лимфолейкоза. Гематол трансфузиол 1998;(5):6—11.
2. Montserrat E. CLL therapy: progress at last! Blood 2005;105(1):2—3.
3. Chemotherapeutic options in chronic lymphocytic leukemia: a meta-analysis of the randomized trials. CLL Trialists' Collaborative Group. J Natl Cancer Inst 1999;91:861—8.
4. Бессмельцев С.С. Современные подходы к управлению хроническим лимфолейкозом. Вестн гематол 2007;3(1):50—64.
5. Rai K.R., Peterson B.L., Appelbaum F. et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000;343:1750—7.
6. Бессмельцев С.С. Флударабин в терапии больных хроническим лимфолейкозом. Медицина 2006;(4):92—101.
7. Hale G., Swirsky D.V., Hayhoe F.G., Waldmann H. Effects of monoclonal antilymphocyte antibodies in vivo in monkeys and humans. Mol Biol Med 1983;1: 321—34.
8. Cavalli-Björkman N., Osby E., Lundin J. et al. Fatal adenovirus infection during alemtuzumab (anti-CD52 monoclonal antibody) treatment of a patient with fludarabine-refractory B-cell chronic lymphocytic leukemia. Med Oncol 2002;19:277—80.
9. Бялик Т.Е., Гривцова Л.Ю., Карселадзе А.И. и др. Некоторые прогностические факторы при современной терапии хронического лимфолейкоза. Совр онкол 2006;(4):16—9.
10. Бессмельцев С.С., Алексеева Ю.А., Морозова Е.В. и др. Первые результаты применения алемтузумаба (кэмпаса) в лечении В-клеточного хронического лимфолейкоза и Т-клеточных неходжкинских лимфом. Вестн гематол 2007;(4):5—14.
11. Rai K.R., Freter C.E., Mercier R.J. et al. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine. J Clin Oncol 2002;20:3891—7.
12. Osterborg A., Karlsson C., Lundin J. et al. Strategies in the management of alemtuzumab-related side effects. Semin Oncol 2006;33(Suppl 5):29—35.
13. Lundin J., Kimby E., Björkholm M. et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002;100: 768—73.
14. Бессмельцев С.С., Волкова М.А., Голубева М.Е. и др. Рекомендации по обследованию и лечению больных В-клеточным хроническим лимфолейкозом. Совр Онкол 2007; экстравыпуск.
15. Elter Т., Borchmann P., Schulz H. et al. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: results of a phase II trial. J Clin Oncol 2005;23:7024—31.
16. Rieger K., Von Grünhagen U., Fietz T. et al. Efficacy and tolerability of alemtuzumab (CAMPATH-1H) in the salvage treatment of B-cell chronic lymphocytic leukemia — change of regimen needed? Leuk Lymphoma 2004;45:345—9.
17. Montillo M., Cafro A.M., Tedeschi A. et al. Safety and efficacy of subcutaneous Campath-1H for treating residual disease in patients with chronic lymphocytic leukemia responding to fludarabine. Haematologica 2002;87(7):695—700.
Review
For citations:
Bessmeltsev S.S., Litvinskaya E.V., Abdulkadirov K.M., Karyagina E.V. Alemtuzumab in treatment of chronic lymphocytic leukemia. Oncohematology. 2009;(3):15-22. (In Russ.) https://doi.org/10.17650/1818-8346-2009-0-3-15-22
Views:
139
Email this article 